In a groundbreaking development for neurodegenerative disease research, doctors have tested a one-time gene therapy designed to slow – and potentially alter – the course of Huntington’s disease. The experimental treatment, AMT-130, developed by uniQure, represents the first time a genetic therapy has been delivered directly into the brain for this condition.

A New Approach to a Devastating Disease

Huntington’s disease is a fatal, inherited disorder caused by a mutation in the HTT gene, which leads to the production of a toxic protein that damages brain cells. Symptoms typically appear in adulthood and progressively affect movement, cognition, and mental health.

AMT-130 uses a harmless viral vector to deliver a small piece of genetic code, known as microRNA, into the brain. This microRNA switches off the production of the mutant protein at its genetic source. The treatment is delivered via a single, complex brain surgery lasting up to 18 hours – but it is designed to be a one-time intervention.

Early Trial Results

In a three-year Phase 1/2 clinical trial involving 29 participants, 17 patients received a high dose of the therapy and 12 a low dose. There was no placebo group, so the results were compared against historical data of disease progression.

Patients receiving the treatment showed a 75% slower decline in motor and cognitive function compared with what would typically be expected over three years – a potentially meaningful difference for patients and families facing this relentless disease. Importantly, no serious treatment-related side effects were reported.

While the difference narrowly missed the threshold for a clinically noticeable change, experts have called the results “promising” and “a potential major step” in Huntington’s research.

Cautious Optimism

Despite encouraging signals, experts urge caution. The data has not yet been peer-reviewed, and the small sample size limits definitive conclusions. Past gene therapy candidates for Huntington’s have shown early promise only to fall short in later-stage trials – highlighting the need for careful validation.

As Professor David Rubinsztein of the Cambridge Institute for Medical Research noted, “The results are encouraging, but it is early days, and we have been here before with other similar therapies.”

What’s Next?

UniQure is continuing to evaluate AMT-130 in ongoing Phase 1/2 studies in both the U.S. and Europe, refining dosage and assessing long-term safety. If successful, the company plans to seek regulatory approval in the near future.

The Bigger Picture: Gene Therapy and Neuroscience

This development sits within a wider movement towards precision gene therapies for neurological diseases. Companies such as Biogen and Lexeo Therapeutics are exploring similar strategies for conditions including Alzheimer’s, aiming to target the root causes of neurodegeneration rather than only managing symptoms.

If proven effective, therapies like AMT-130 could mark a turning point – not only for Huntington’s disease but for the broader field of genomic medicine.

At Woodley BioReg, we continue to follow advances in gene therapy and regulatory science that are shaping the future of healthcare innovation. As global momentum builds around next-generation treatments, the path from research to regulatory approval will be pivotal in ensuring that safe, effective, and life-changing therapies reach patients worldwide.

Back to News + Insights